Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: Biological rationale and clinical applications

Expert Review of Anticancer Therapy

Volumn 15, Issue 2, 2015, Pages 235-245

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

gastric cancer; HGF; MET; systemic treatment; targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; FICLATUZUMAB; FORETINIB; IRINOTECAN; KRC 408; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ONARTUZUMAB; RILOTUMUMAB; SCATTER FACTOR; T 1840383; TIVANTINIB; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOMA; ANIMAL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; STOMACH NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84921460787     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.974564     Document Type: Review

References (78)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90
2. Available from: http://globocan. iarc. fr/old/ FactSheets/cancers/stomach-new. asp [Accessed online on 19 July 2014]
3. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer; preclinical and clinical aspects. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
4. American Cancer Society Cancer facts and figures 2011. American Cancer Society; Atlanta, GA: 2011
5. Forman D, Burley V. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006;20:633-49
6. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241
7. Fitzgerald R, Hardwick R, Huntsman D. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47:436-44
8. Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol 2014;90:68-76
9. Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011;17: 2693-701
10. Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur J Cancer 2014
11. Giordano S, Ponzetto C, Di Renzo MF, et al. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989;339(6220):155-6
12. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991;6(4):501-4
13. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77(2):261-71
14. Sipeki S, Bander E, Buday L, et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 1999;11(12):885-90
15. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12(2):89-103
16. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11(12):834-48
17. Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle 2005; 4(4):518-20
18. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87(10):1063-9
19. Mok T, Park K, Geater SL. A randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (pts) with lung adenocarcinoma (LA). Ann Oncol 2012;23(Suppl 9):1198P
20. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29(24):3307-15
21. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31(32):4105-14
22. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 1992;7(1):181-5
23. Eng C, Hart LL, Severtsev A, et al. A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. J Clin Oncol 2013;(Suppl 31):abstr 3508
24. Eng C, Van Cutsem E, Nowara E, et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses. J Clin Oncol 2011; 29(Suppl):3500
25. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3(7): 1059-66
26. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14(1): 55-63
27. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60(6):1113-17
28. Pisters LL, Troncoso P, Zhau HE, et al. C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154(1):293-8
29. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
30. Exelixis Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Näve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer. Available from: http:// clinicaltrials.gov/ct2/show/NCT01995058. NLM identifier: NCT01995058 [Accessed 23 July 2014]
31. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013;24(2):343-9
32. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31(2):181-6
33. Choueiri TK, Pal SK, McDermott DF, et al. Activity of cabozantinib (XL184) in patients (pts) with metastatic. refractory renal cell carcinoma (RCC) J Clin Oncol 2012;30(Suppl 5):364
34. Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107(2):325-33
35. Tsujimoto H, Sugihara H, Hagiwara A, Hattori T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997;431(6):383-9
36. Sun Y, Tian MM, Zhou LX, et al. Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population. Chin J Cancer Res 2012;24(1): 18-22
37. Zhao L, Yasumoto K, Kawashima A, et al. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci 2013;104(12):1640-6
38. Liu YJ, Shen D, Yin X, et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer 2014;110(5):1169-78
39. Yu S, Yu Y, Zhao N, et al. c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One 2013;8(11):e79137
40. Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014;15(9): 1007-18
41. Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107(2):325-33
42. Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011;29(36):4789-95
43. Kurokawa Y, Matsuura N, Kawabata R, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol 2014;1-7, in press
44. Ma J, Ma J, Meng Q, et al. Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma. Pathol Oncol Res 2013;19(4): 821-32
45. Wu JG, Yu JW, Wu HB, et al. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC research notes 2014;7(1):6
46. Guo T, Yang J, Yao J, et al. Expression of MACC1 and c-Met in human gastric cancer and its clinical significance. Cancer Cell Int 2013;13(1):121
47. Betts G, Valentine H, Pritchard S, et al. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch 2014; 464(2):145-56
48. An X, Wang F, Shao Q, et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer 2014;120(5):675-82
49. Graziano F, Catalano V, Lorenzini P, et al. Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics J 2014;14(5):418-23
50. Peng Z, Zhu Y, Wang Q, et al. Prognostic Significance of MET Amplification and Expression in Gastric Cancer: a Systematic Review with Meta-Analysis. PLoS One 2014;9(1):e84502
51. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010;9(2):400-9
52. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013;110(32):E2987-96
53. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013;14(6):472-80
54. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor.
55. Clin Cancer Res 2010;16(13):3507-16
56. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12):2298-308
57. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9(6):1544-53
58. Awazu Y, Nakamura K, Mizutani A, et al. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Mol Cancer Ther 2013;12(6):913-24
59. Yashiro M, Nishii T, Hasegawa T, et al. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer 2013;109(10):2619-28
60. Hong SW, Jung KH, Park BH, et al. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer Lett 2013;332(1):74-82
61. Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012;11(7): 1557-64
62. Kawakami H, Okamoto I, Arao T, et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013;4(1):9
63. Funakoshi Y, Mukohara T, Tomioka H, et al. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs 2013;31(5):1158-68
64. Jardim DL, de Melo GD, Falchook GS, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 2014;5(7):1837-45
65. Lee YY, Kim HP, Kang MJ, et al. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ ERK in lapatinib-resistant cancer cell line. Exp Mol Med 2013;45(11):e64
66. Kang YK, Muro K, Ryu MH, et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second-or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs 2014; 32(2):355-61
67. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8(3):e54014
68. Jhawer MP, Kindler HL, Wainberg ZA, et al. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. J Clin Oncol 2008;26:4572
69. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29(36):4803-10
70. Doi T, Yamaguchi K, Komatsu Y, et al. Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. J Clin Oncol meeting abstracts 2014; 32(15-Suppl):4051
71. Catenacci DV, Henderson L, Xiao SY, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011;1(7):573-9
72. A Study of LY2875358 in participants with MET positive, advanced gastric cancer. Available from: https://clinicaltrials.gov/ct2/ results?term=NCT01874938&Search=Search
73. Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1. Available from: https://clinicaltrials.gov/ct2/ results?term=NCT02034981&Search=Search
74. First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET)-Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/results? term=NCT01697072&Search=Search
75. A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer. Available from: https://clinicaltrials.gov/ct2/ results?term=NCT02137343&Search=Search
76. A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric). Available from: https:// clinicaltrials.gov/ct2/results? term=NCT01662869&Search=Search
77. MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/results? term=NCT01443065&Search=Search
78. Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. Available from: https://clinicaltrials.gov/ct2/ results?term=NCT02016534&Search=Search